What the FDA labels say about taking them together
Digoxin and mirabegron
Digoxin's FDA label of December 5, 2024 names mirabegron in its drug interactions section, and mirabegron's label names digoxin too. The mirabegron label: “When initiating a combination of mirabegron and digoxin, use the lowest dose of digoxin; monitor serum digoxin concentrations to titrate digoxin dose to desired clinical effect. …”
Check it at the source: the digoxin FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.); the mirabegron FDA label on DailyMed (effective December 24, 2025, Lupin Pharmaceuticals, Inc.).
What does the digoxin label say about mirabegron?
Digoxin label, drug interactionsMirabegron; 29%; 27%; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the dosing frequency and continue monitoring.
Lanoxin label (Covis Pharma US, Inc, October 17, 2025), drug interactionsMirabegron; 29%; 27%
Source: FDA drug label (Digoxin, NDA021648), Hikma Pharmaceuticals USA Inc., effective April 10, 2025 (SPL set 1b7e5c6e-e052-41b0-a4ce-05dfe62faaaf), via openFDA
Source: FDA drug label (Lanoxin, NDA009330), Covis Pharma US, Inc, effective October 17, 2025 (SPL set 9ec84cac-6ecc-43dc-8006-6ccc029e2707), via openFDA
Source: FDA drug label (LANOXIN), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set d91e3646-4c63-4512-ab22-db39c085c4dc), via openFDA; the full label on DailyMed
What does the mirabegron label say about digoxin?
Mirabegron label, drug interactionsWhen initiating a combination of mirabegron and digoxin, use the lowest dose of digoxin; monitor serum digoxin concentrations to titrate digoxin dose to desired clinical effect. ( 7.2 , 12.3 ) Pediatric use information is approved for Astellas Pharma Global Development, Inc.'s MYRBETRIQ (mirabegron extended-release tablets).
Myrbetriq label (Astellas Pharma US, Inc., August 1, 2024), drug interactionsWhen initiating a combination of mirabegron and digoxin with or without solifenacin succinate, use the lowest dose of digoxin; monitor serum digoxin concentrations to titrate digoxin dose to desired clinical effect.
Source: FDA drug label (Myrbetriq, NDA202611), Astellas Pharma US, Inc., effective August 1, 2024 (SPL set ba9e9e15-e666-4c56-9271-2e24739cfa2d), via openFDA
Source: FDA drug label (MIRABEGRON), Lupin Pharmaceuticals, Inc., effective December 24, 2025 (SPL set d22d3d12-8466-46db-bc19-d13e87c6115c), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Digoxin | Mirabegron | |
|---|---|---|
| Labeled for | Heart failure, Atrial fibrillation | Overactive bladder |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.133 per tablet 125 mcg tablet | $9.39 per tablet 50 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once